Technical Analysis for BEAM - Beam Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 34.07 | -3.80% | -1.35 |
BEAM closed down 3.8 percent on Monday, March 18, 2024, on 66 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -3.80% | |
Wide Bands | Range Expansion | -3.80% | |
Oversold Stochastic | Weakness | -3.80% | |
Fell Below 20 DMA | Bearish | -1.57% | |
Stochastic Reached Oversold | Weakness | -1.57% | |
Wide Bands | Range Expansion | -1.57% | |
Oversold Stochastic | Weakness | -1.57% |
Alert | Time |
---|---|
Possible NR7 | about 18 hours ago |
Down 3% | about 22 hours ago |
Rose Above Previous Day's High | about 22 hours ago |
Down 2 % | about 22 hours ago |
Down 1% | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/26/2024
Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Acute Lymphoblastic Leukemia Sickle Cell Disease Acute Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Leukemia Central Nervous System Disorders Nervous System Disorders Antitrypsin Deficiency Acute Lymphoblastic Leukemia Sickle Cell Disease Acute Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 49.5 |
52 Week Low | 16.95 |
Average Volume | 1,409,437 |
200-Day Moving Average | 27.88 |
50-Day Moving Average | 30.98 |
20-Day Moving Average | 36.91 |
10-Day Moving Average | 36.51 |
Average True Range | 2.63 |
RSI (14) | 47.92 |
ADX | 35.85 |
+DI | 25.15 |
-DI | 17.91 |
Chandelier Exit (Long, 3 ATRs) | 41.62 |
Chandelier Exit (Short, 3 ATRs) | 38.56 |
Upper Bollinger Bands | 43.61 |
Lower Bollinger Band | 30.22 |
Percent B (%b) | 0.29 |
BandWidth | 36.29 |
MACD Line | 1.14 |
MACD Signal Line | 1.97 |
MACD Histogram | -0.8297 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 36.60 | ||||
Resistance 3 (R3) | 36.87 | 36.30 | 36.18 | ||
Resistance 2 (R2) | 36.30 | 35.65 | 36.16 | 36.04 | |
Resistance 1 (R1) | 35.18 | 35.25 | 34.89 | 34.91 | 35.90 |
Pivot Point | 34.61 | 34.61 | 34.46 | 34.47 | 34.61 |
Support 1 (S1) | 33.49 | 33.96 | 33.20 | 33.22 | 32.23 |
Support 2 (S2) | 32.92 | 33.56 | 32.78 | 32.09 | |
Support 3 (S3) | 31.80 | 32.92 | 31.95 | ||
Support 4 (S4) | 31.53 |